Why the study?
The study was conducted to develop a recombinant antigen for a vaccine prototype effective against a wide range of rotaviruses.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Extends rotavirus antigen design options; leaves open safety and efficacy in humans.
The present work is concerned with development of recombinant antigen for the vaccine prototype. The vaccine is going to be effective against a wide range of rotaviruses. Antigen VP8+875x6 was developed on the basis of VP8 protein. It also includes several neutralizing epitopes from rotaviral proteins VP8, VP5 and VP7.
No takes yet. Share an insight, caveat, or question.
Evtushenko et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: